agreed to discover, develop, and commercialize mAbs targeting antigens discovered by Human Genome Services in the fields of oncology and immunology
. Morphotek will be responsible for validating targets found in HGS genomic research, developing antibody candidates, and conducting preclinical proof-of-concept studies. Companies may choose to opt in to participate in further development and commercialization, with costs dependent on the individual situation.
"The rapid commercialization of our late-stage compounds continues to be the priority focus of HGS," says H. Thomas Watkins, president and CEO of HGS. "At the same time, we also remain committed to advancing our earlier and mid-stage programs in development to ensure sustainable growth well into the future."
In the past three years, HGS has identified approximately 50 therapeutic and diagnostic targets for further research and potential development through future collaborations such as the one with Morphotek, says the company.